Back to Journals » Pediatric Health, Medicine and Therapeutics » Volume 10

Relationship of glucose-6-phosphate dehydrogenase deficiency and neonatal sepsis: a single-center investigation on the major cause of neonatal morbidity and mortality

Authors Zekavat OR, Makarem A, Bahrami R, Dastgheib N, Dehghani SJ

Received 21 January 2019

Accepted for publication 20 March 2019

Published 11 April 2019 Volume 2019:10 Pages 33—37

DOI https://doi.org/10.2147/PHMT.S202080

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Roosy Aulakh

Download Article [PDF] 

Omid Reza Zekavat,1 Alireza Makarem,2 Reza Bahrami,3 Niloofar Dastgheib,4 Seyed Javad Dehghani5

1Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 2Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran; 3Neonatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 4Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran; 5Neshat Laboratory Research Center, Shiraz, Iran

Introduction: Neonatal sepsis is a serious disease with distinct clinical and laboratory findings. G6PD deficiency is known as the most common human erythrocyte-enzyme deficiency. This study was designed to investigate the relationship between G6PD deficiency and neonatal sepsis, since it is a major cause of neonatal morbidity and mortality.
Methods: A cross-sectional case–control study was designed and performed on 50 neonates who had been admitted to the neonatal intensive-care unit and diagnosed with sepsis and 50 normal neonate controls. Quantitative G6PD-enzyme activity was assessed in the case and control groups.
Results: Quantitative G6PD-level assessment showed that five (5%) subjects in the case group vs one (1%) of the control group were severely deficient and nine (9%) cases vs one (1%) control were moderately deficient. Enzyme-level differences were statistically significant (P=0.003).
Conclusion: Our study showed higher incidence of G6PD deficiency in neonates who had been admitted due to sepsis. We suggest quantitative G6PD-level assessment instead of the routine qualitative methods in prevalent G6PD deficiency. It is also recommended that neonates with G6PD deficiency be under close supervision during the first month of life, especially those with other risks of neonatal sepsis, such as prematurity or low birth weight.

Keywords: G6PD, neonatal sepsis, morbidity

Introduction

Neonatal sepsis is a serious disease with defined clinical and laboratory findings, which is confirmed through positive blood culture. If is not diagnosed rapidly and treated completely, it can lead to permanent disability, multiple organ failure, shock or death.1,2

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is present in more than 400 million people worldwide as the most common erythrocyte human enzyme deficiency, with the highest prevalence in Asia, Africa, the Mediterranean and the Middle East.3 According to the world health organization (WHO), the prevalence of G6PD deficiency is 10–14.9% in Iran. A study on the prevalence of G6PD deficiency in Fars province (southern Iran) showed that 1.8% of all females and 12% of males had G6PD deficiency4,5,17

The exact mechanism for higher prevalence of sepsis in male neonates is not clear.18 This x-linked recessive enzyme deficiency presents in a spectrum of clinical manifestations such as infection, neonatal jaundice, chronic anemia, and drug induced hemolysis.7 Also, G6PD enzyme plays a major role in glucose metabolism, and its presence is vital for nicotinamide adenine dinucleotide phosphate (NADPH) production. One of the NADPH functions is glutathione reduction, which detoxifies and neutralizes the oxidants.

This hypothesis proposes that G6PD deficiency significantly reduces the NADPH content of white blood cells (WBCs); hence, it negatively affects the fighting ability against invasive bacterial infection.812 Few studies have shown the relationship between G6PD deficiency and increase in the incidence of some infections like viral hepatitis, post-operation infection and sepsis.6 Since neonatal sepsis is a major cause of neonatal morbidity and mortality, this study was designed to investigate the relationship between G6PD deficiency and neonatal sepsis.

Material and methods

A cross-sectional case control study was designed and performed on 50 neonates who were admitted to neonatal intensive care unit (NICU) diagnosed with sepsis in Zeynabieh hospital affiliated to Shiraz University of Medical Sciences from January 2017 to January 2018. Also, 50 healthy controls (neonate who referred to Zeynabieh clinic for a routine check up and vaccination) were included in this study. Written informed consent was obtained from all the patients and control’s parents/guardians. The Ethics Committee of Jahrom University of Medical Sciences approved the study with the code number of Jums.REC.1393.129.

Before the administration of antibiotic, blood sample site was prepared according to the CLSI guidelines. Then, the whole blood sample was taken from all the neonates (1cc) in EDTA tube, and transferred to Neshate laboratory complex stored in cool = box at 2–8 °C. Red blood cells’ G6PD enzyme level was quantitatively measured by Hitachi 911 full-automatic device (Weber company kit, Japan). Enzyme activity was determined by the international unit per gram of haemoglobin (IU/gHb). In this method, the normal enzyme activity reference range was ≥6.5 IU/gHb. Enzyme activity levels between 1.5 and 6.5 IU/gHb were considered as intermediate deficiency and below 1.5 IU/gHb as severe deficiency.

The inclusion criteria were neonates who had been admitted to NICU with C-reactive protein level greater than 6 mg/lit, 5,000≤ WBC ≥25,000 (mcl), immature neutrophils/total neutrophils greater than 0.2, and positive or negative blood culture. The exclusion criteria were rejection of the patients’ guardian for taking blood sample and patients who were admitted to NICU with different diagnosis such as respiratory distress, metabolic disorders and prematurity.

Data analysis

Data analysis was performed using SPSS, version 20. Comparison of qualitative variables between the groups was done using Chi-square test, and the comparison of the quantitative variables between the two groups was done by Student's t-test. P-values <0.05 were considered to be statistically significant.

Result

This study was performed on fifty NICU admitted neonates as the case group (27(54%) male and 23(46%) female) and fifty normal neonates as the control group (20(40%) cases male and 30(60%) female). The results of t-test for comparing the mean age and Apgar score of the neonates showed that the relationship between the two groups was not significant (Table 1). Mann-Whitney U test results showed no significant difference between the mean values of hemoglobin in both groups (Table 1). The results of Chi-square test showed that the association between the two groups regarding gender was not significant (Table 1). The mean hemoglobin levels in the case and control groups were 14.3±2.75 and 13.9±2.84, respectively, which was not statistically significant. The first minute Apgar score was not statistically significant between the two groups. Gender distributions of G6PD deficiency was statistically significant (Table 2).

Table 1 Demographic and clinical data of the two groups: normal and sepsis

Table 2 Association of G6PD enzyme level between the two groups (sepsis and normal)

quantitative G6PD enzyme level assessment in the case and control groups showed that 5 (5%) of the cases vs 1 (1%) of the controls were severely deficient (G6PD enzyme level <1.5), 9 (9%) of the cases vs 1 (1%) of the controls were moderately deficient (G6PD enzyme level: 1.5–6.5), and 36 (36%) of the cases vs 48 (48%) of the controls were normal (G6PD enzyme level (>6.5)). There was a higher rate of G6PD deficiency in the sepsis group than the control group (P=0.003). Regarding the non-match of SEX with group factor at the beginning of the study (according to Table1), the relationship between G6PD and group with a control on sex should be monitored.

Table 2 showed that although all six people who were G6PD deficient were male and that the relationship between G6PD and group was not significant in men (p=0.09), but the relation between G6PD and group in female is significant (p=0.04).

Discussion

G6PD enzyme deficiency, as the most common human enzyme deficiency is an X-linked recessive disease. G6PD deficiency may present itself as an acute hemolytic anemia and neonatal jaundice after ingestion of fava beans (favism) and some drugs.13,14

The enzyme deficiency is related to some degrees of immune deficiency, but few studies have been conducted on the relationship between enzyme deficiency and incidence of neonatal sepsis development. The exact mechanism that can explain the relationship of neonatal sepsis incidence with G6PD deficiency is still unknown. One of the hypotheses states reactive oxygen species synthesis reduction due to NADPH shortage affects the immune system. However, due to G6PD deficiency, produced NADPH is not enough to neutralize all the oxidants produced. Consequently, these oxidants cause damage and apoptosis of the neutrophils.10

Another study states that increased risk of sepsis is due to serum iron level increment related to hemolysis. For example, Oppenheimer reported that intramuscular injection of iron increased the prevalence of sepsis in the meningitis patients.15 For more accurate study of G6PD enzyme level, we evaluated it qualitatively, but we took it into account quantitatively.

Our study showed a higher incidence of G6PD deficiency in neonates who were admitted with impression of sepsis. Ardati et al concluded in their research that the reduced activity of G6PD to as low as 23% of the normal does not affect the neutrophil function.6

Cooper et al reported that G6PD deficiency increased the overall chance of infection likewise,16 G6PD deficiency did not increase the neonatal sepsis risk in a study by Zareifar et al,17 but Rostami-Far et al’s study revealed a higher prevalence of deficiency in the patient group in comparison with the controls.18 some of limitations of this study were: Parental dissatisfaction for participating in the study and taking blood samples, High cost of doing laboratory tests and the low rate of G6PD deficiency in the control group. We were able to confirm higher G6PD deficiency frequency in septic neonates than control group. Also, we can take G6PD deficient neonate into consideration at risk of sepsis, but true risk assessment of G6PD deficiency with neonatal sepsis requires a multi-center cohort study, which into account takes the duration of admission, suspicions to sepsis and confirmed morbidity and mortality due to sepsis into account. Although the association between G6PD and group was not significant in men (0.09) but it was close to nominal level (0.05) and if the sample size is higher, the design is more stable and the association of G6PD and group could be significant in male.

We also suggest quantitative G6PD level assessment instead of routine qualitative methods in prevalent G6PD deficiency regions because the quantitative test is more sensitive and can show the severity of enzyme deficiency (normal, deficient and intermediate) and can identify heterozygotes that were not detected using the spectrophotometric G6PD assay alone.19

Also, it is recommended that the deficient neonates should be under close supervision during the first month of life, especially those with other risks of neonatal sepsis like prematurity or low birth weight.

Ethical approval

This study was approved by the local Ethics Committee of Jahrom University of Medical Sciences (code number of Jums.REC.1393.129) and written informed consent was obtained from a parent for each of the participants. This study was conducted in accordance with the Declaration of Helsinki.

Acknowledgments

The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, and also Center for Development of Clinical Research of Nemazee Hospital and Dr Nasrin Shokrpour for editorial assistance.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014;27:21–47. doi:10.1128/CMR.00031-13

2. Farhadi R, Yaghobian M, Saravi BM. Clinical findings leading to the diagnosis of sepsis in neonates hospitalized in Imam Khomeini and Bu Ali hospitals, Sari, Iran: 2011–2012. Glob J Health Sci. 2014;6:298–303. doi:10.5539/gjhs.v6n4p298

3. Friedman MJ, Trager W. The biochemistry of resistance to malaria. Sci Am. 1981;244:154–155, 158–164. doi:10.1038/scientificamerican0381-154

4. WHO working group. Word map of G6PD deficiency. Bull World Health Organ. 1989;67(6):601–611.

5. Cohan N, Karimi M, Khalili A, Falahzadeh MH, Samadi B, Mahdavi MR. The efficacy of a neonatal screening programme in decreasing the hospitalization rate of patients with G6PD deficiency in southern Iran. J Med Screen. 2010;17(2):66–67. doi:10.1258/jms.2010.009105

6. Ardati KO, Bajakian KM, Tabbara KS. Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function. Acta Haematol. 1997;97(4):211–215. doi:10.1159/000203685

7. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency and severe neonatal hyperbilirubinemia: a complexity of interactions between genes and environment. Semin Fetal Neonatal Med. 2010;15:148–156. doi:10.1016/j.siny.2009.10.007

8. Reier-Nilsen T, Farstad T, Nakstad B, Lauvrak V, Steinbakk M. Comparison of broad range 16S rDNA PCR and conventional blood culture for diagnosis of sepsis in the newborn: a case control study. BMC Pediatr. 2009;9:5. doi:10.1186/1471-2431-9-5

9. Iranpour R, Hashemipour M, Talaei S-M, Soroshnia M, Amini A. Newborn screening for glucose-6-phosphate dehydrogenase deficiency in Isfahan, Iran: a quantitative assay. J Med Screen. 2008;15:62–64. doi:10.1258/jms.2008.008027

10. Robinson JM. Reactive oxygen species in phagocytic leukocytes. Histochem Cell Biol. 2008;130:281–297. doi:10.1007/s00418-008-0461-4

11. Wolach B, Ashkenazi M, Grossmann R, et al. Diurnal fluctuation of leukocyte G6PD activity. A possible explanation for the normal neutrophil bactericidal activity and the low incidence of pyogenic infections in patients with severe G6PD deficiency in Israel. Pediatr Res. 2004;55:807–813. doi:10.1203/01.PDR.0000120680.47846.47

12. Elyassi AR, Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: a review of literature. Anesth Prog. 2009;56:86–91. doi:10.2344/0003-3006-56.3.86

13. Minucci A, Giardina B, Zuppi C, Capoluongo E. Glucose-6-phosphate dehydrogenase laboratory assay: how, when, and why? IUBMB Life. 2009;61:27–34. doi:10.1002/iub.137

14. Zhang P, Gao X, Ishida H, et al. An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines. Am J Trop Med Hyg. 2013;88:1138–1145. doi:10.4269/ajtmh.12-0682

15. Oppenheimer SJ. Iron and its relation to immunity and infectious disease. J Nutr. 2001;13:616S–633S. doi:10.1093/jn/131.2.616S

16. Cooper MR, DeChatelet LR, McCall CE, LaVia MF, Spurr CL, Baehner RL. Complete deficiency of leukocyte glucose-6 phosphate dehydrogenase with defective bactericidal activity. J Clin Invest. 1972;51:769–778. doi:10.1172/JCI106871

17. Zareifar S, Pishva N, Farahmandfar M, Benaei S, Cohan N. Prevalence of G6PD deficiency in neonatal sepsis in Iran. Iran J Pediatr. 2014;24:115–116.

18. Rostami-Far Z, Ghadiri K, Rostami-Far M, Shaveisi-Zadeh F, Amiri A, Rahimian Zarif B. Glucose-6-phosphate dehydrogenase deficiency(G6PD) as a risk factor of male neonatal sepsis. J Med Life. 2016;9:34–38.

19. Reclos GJ, Hatzidakis CJ, Schulpis KH. Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening. J Med Screen. 2000;7(1):46–51. doi:10.1136/jms.7.1.46

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]